ADMA Biologics Management
Management criteria checks 3/4
ADMA Biologics' CEO is Adam Grossman, appointed in Jan 2007, has a tenure of 17.83 years. total yearly compensation is $6.04M, comprised of 12.4% salary and 87.6% bonuses, including company stock and options. directly owns 1.07% of the company’s shares, worth $52.03M. The average tenure of the management team and the board of directors is 0.8 years and 12.3 years respectively.
Key information
Adam Grossman
Chief executive officer
US$6.0m
Total compensation
| CEO salary percentage | 12.4% |
| CEO tenure | 17.8yrs |
| CEO ownership | 1.1% |
| Management average tenure | less than a year |
| Board average tenure | 12.3yrs |
Recent management updates
Recent updates
ADMA Biologics, Inc.'s (NASDAQ:ADMA) 27% Price Boost Is Out Of Tune With Revenues
Oct 09
ADMA Biologics: Riding High On ASCENIV's Success
Oct 02ADMA Biologics, Inc.'s (NASDAQ:ADMA) Intrinsic Value Is Potentially 57% Above Its Share Price
Sep 06ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality
Aug 16ADMA Biologics: A Compelling GARP Stock For Biotech Investors
Jul 27ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Jul 24Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?
Jul 17Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?
May 30ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next
May 13Giving ADMA Biologics A Well-Deserved 'Booyah'
May 12ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares
May 08Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?
Apr 04Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)
Apr 03ADMA Biologics: On A Roll Entering 2024
Jan 19Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?
Jan 09ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Jan 09We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Oct 25We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Jun 10The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet
May 12ADMA Biologics: Strong Growth Is Clearing The Path To Profitability
Aug 21ADMA Biologics GAAP EPS of -$0.07, revenue of $33.9M
Aug 10ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Jun 01ADMA Biologics: A Path To Profits Looks Clear
May 12ADMA: Pertinent Updates
Apr 18ADMA Biologics' 2021 Numbers Showed Continued Strong Execution
Mar 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$68m |
| Jun 30 2024 | n/a | n/a | US$35m |
| Mar 31 2024 | n/a | n/a | -US$4m |
| Dec 31 2023 | US$6m | US$750k | -US$28m |
| Sep 30 2023 | n/a | n/a | -US$23m |
| Jun 30 2023 | n/a | n/a | -US$40m |
| Mar 31 2023 | n/a | n/a | -US$48m |
| Dec 31 2022 | US$3m | US$637k | -US$66m |
| Sep 30 2022 | n/a | n/a | -US$70m |
| Jun 30 2022 | n/a | n/a | -US$73m |
| Mar 31 2022 | n/a | n/a | -US$78m |
| Dec 31 2021 | US$4m | US$618k | -US$72m |
| Sep 30 2021 | n/a | n/a | -US$74m |
| Jun 30 2021 | n/a | n/a | -US$74m |
| Mar 31 2021 | n/a | n/a | -US$75m |
| Dec 31 2020 | US$2m | US$600k | -US$76m |
| Sep 30 2020 | n/a | n/a | -US$67m |
| Jun 30 2020 | n/a | n/a | -US$61m |
| Mar 31 2020 | n/a | n/a | -US$54m |
| Dec 31 2019 | US$2m | US$536k | -US$48m |
| Sep 30 2019 | n/a | n/a | -US$56m |
| Jun 30 2019 | n/a | n/a | -US$59m |
| Mar 31 2019 | n/a | n/a | -US$61m |
| Dec 31 2018 | US$2m | US$536k | -US$66m |
| Sep 30 2018 | n/a | n/a | -US$61m |
| Jun 30 2018 | n/a | n/a | -US$61m |
| Mar 31 2018 | n/a | n/a | -US$55m |
| Dec 31 2017 | US$3m | US$494k | -US$44m |
Compensation vs Market: Adam's total compensation ($USD6.04M) is about average for companies of similar size in the US market ($USD7.97M).
Compensation vs Earnings: Adam's compensation has been consistent with company performance over the past year.
CEO
Adam Grossman (47 yo)
17.8yrs
Tenure
US$6,039,649
Compensation
Mr. Adam S. Grossman serves as Director at BioFlorida Inc since August 2021. He is the Co-Founder of ADMA Biologics, Inc. and has been its Chief Executive Officer and President since October 2011 and 2007...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 17.8yrs | US$6.04m | 1.07% $ 52.0m | |
| Co-Founder & Vice Chairman of the Board | 17.8yrs | US$284.72k | 0.22% $ 10.5m | |
| CFO & Treasurer | less than a year | no data | 0.091% $ 4.4m | |
| COO & Senior VP of Compliance | less than a year | no data | 0.055% $ 2.7m | |
| Vice President of Marketing & Corporate Development | no data | no data | no data | |
| Executive Director of Sales | less than a year | no data | no data | |
| Vice President of Human Resources | 2.8yrs | no data | no data | |
| Senior Director of Business Development & Corporate Strategy | no data | no data | no data |
0.8yrs
Average Tenure
49yo
Average Age
Experienced Management: ADMA's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 17.8yrs | US$6.04m | 1.07% $ 52.0m | |
| Co-Founder & Vice Chairman of the Board | 17.8yrs | US$284.72k | 0.22% $ 10.5m | |
| Independent Director | 12.5yrs | US$280.72k | 0.025% $ 1.2m | |
| Independent Chairman | 17.8yrs | US$290.22k | 0.022% $ 1.1m | |
| Independent Director | 3.1yrs | US$272.34k | 0.097% $ 4.7m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 12.3yrs | US$275.09k | 0.060% $ 2.9m | |
| Member of Scientific Advisory Board | 10.4yrs | no data | no data | |
| Member of Scientific Advisory Board | 10.4yrs | no data | no data | |
| Independent Director | 1.1yrs | US$231.12k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
12.3yrs
Average Tenure
60yo
Average Age
Experienced Board: ADMA's board of directors are seasoned and experienced ( 12.3 years average tenure).